Haemonetics Corporation (NYSE:HAE) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Haemonetics Corporation has received an average rating of "Moderate Buy" from eleven analysts, with a consensus 12-month target price of $75.89.
• The company recently reported $1.10 earnings per share, exceeding analysts' estimates, although revenue decreased by 4.4% year-over-year.
• Institutional investors hold 99.67% of Haemonetics' stock, with several firms significantly increasing their positions in the company during the third quarter.

Shares of Haemonetics Corporation (NYSE:HAE - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $75.8889.

HAE has been the subject of a number of recent analyst reports. Mizuho dropped their price objective on Haemonetics from $90.00 to $70.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Robert W. Baird initiated coverage on Haemonetics in a research report on Thursday, June 26th. They set an "outperform" rating and a $87.00 target price for the company. Baird R W raised Haemonetics to a "strong-buy" rating in a research report on Wednesday, June 25th. Raymond James Financial lowered Haemonetics from a "strong-buy" rating to an "outperform" rating and decreased their target price for the company from $105.00 to $78.00 in a research report on Monday, August 11th. Finally, Barrington Research reaffirmed an "outperform" rating and set a $86.00 target price on shares of Haemonetics in a research report on Tuesday, September 23rd.

Haemonetics Price Performance

HAE opened at $49.77 on Friday. The business has a fifty day moving average of $51.96 and a 200 day moving average of $62.79. Haemonetics has a 52-week low of $47.31 and a 52-week high of $94.99. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. The stock has a market cap of $2.40 billion, a P/E ratio of 15.22, a PEG ratio of 0.90 and a beta of 0.37.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The company had revenue of $321.39 million during the quarter, compared to analysts' expectations of $305.12 million. During the same quarter in the previous year, the business earned $1.02 EPS. Haemonetics's revenue was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, sell-side analysts anticipate that Haemonetics will post 4.55 EPS for the current year.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC raised its position in Haemonetics by 159.1% during the 3rd quarter. CWM LLC now owns 4,733 shares of the medical instruments supplier's stock valued at $231,000 after purchasing an additional 2,906 shares in the last quarter. Pacer Advisors Inc. bought a new stake in Haemonetics during the 3rd quarter valued at $309,000. Inspire Investing LLC raised its position in Haemonetics by 78.4% during the 3rd quarter. Inspire Investing LLC now owns 9,325 shares of the medical instruments supplier's stock valued at $455,000 after purchasing an additional 4,098 shares in the last quarter. Hunter Perkins Capital Management LLC raised its position in shares of Haemonetics by 150.2% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 17,764 shares of the medical instruments supplier's stock worth $866,000 after acquiring an additional 10,664 shares in the last quarter. Finally, Harbor Capital Advisors Inc. raised its position in shares of Haemonetics by 49.7% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 42,859 shares of the medical instruments supplier's stock worth $2,089,000 after acquiring an additional 14,226 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.